Hikma Pharmaceuticals PLC (HIK.LN), a multinational pharmaceutical group, Friday reiterated its guidance for full year group revenue growth in the low teens and said gross margins would be higher than in 2009.

MAIN FACTS:

-Confirms guidance of low double digit revenue growth for the Branded business for the full year.

-Sales in global injectables business have been accelerating in the second half.

-Continues to expect to deliver at least 20% sales growth in generics business for the full year with a high operating margin.

-Financing position remains strong, allowing the company to actively pursue acquisition opportunities across the business.

-Remains confident that strategy of organic growth supplemented by acquisitions and partnerships will continue to deliver excellent results for the Group.

-Shares at closed Thursday at 783 pence valuing the company at GBP1.51 billion.

-By Peter Evans, Dow Jones Newswires; 44-20-7842-9308; peter.evans@dowjones.com
Hikma Pharmaceuticals (PK) (USOTC:HKMPY)
Historical Stock Chart
From Sep 2024 to Oct 2024 Click Here for more Hikma Pharmaceuticals (PK) Charts.
Hikma Pharmaceuticals (PK) (USOTC:HKMPY)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more Hikma Pharmaceuticals (PK) Charts.